The core business of the company is the manufacture of dental implants and related products used to treat tooth loss, such as abutments, crowns and bridges.

In 1978, the Swedish health authorities approved the insertion of dental implants for clinical purposes, and Brånemark entered into a partnership with Bofors to industrialize his ideas and bring them to a broader market.

In the same year, the U.S. Food and Drug Administration (FDA) approved the use of titanium dental implants in the United States.

In 1993, in need of further sources of funding to continue its expansion and growth plans, Nobelpharma was listed on the Stockholm Stock Exchange in 1994.

In July 2018, Danaher announced its intention to spin off its $2.8 billion dental segment into an independent publicly traded company.

There are several implant types that differ in their shape with their use depending on patients’ medical treatment requirements and the clinician's preference.

Manufacturing plants for dental implants are based in Karlskoga (Sweden), Yorba Linda (USA), and Tel Aviv (Israel).

Under the brand name NobelProcera, Nobel Biocare has a portfolio of dental prosthetic solutions and related components.